MASS Stock Forecast: 908 Devices, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for 908 Devices, Inc. is $14. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 77 of 100 as at 21 Nov 2026 — inside the top quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores 908 Devices, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (87): Sales and profits are climbing, and climbing faster than before.
Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MASS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MASS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2026 | Canaccord Genuity | Maintains | Buy | $14 → $14 |
| 11 Nov 2026 | Stifel | Maintains | Buy | $12 → $14 |
| 10 Sept 2026 | Canaccord Genuity | Initiates | Buy | $14 |
| 12 Aug 2026 | Roth Capital | Maintains | Buy | $11 → $13 |
| 12 Aug 2026 | Stifel | Maintains | Buy | $10 → $12 |
| 29 July 2026 | Roth Capital | Initiates | Buy | $11 |
| 5 Aug 2025 | Leerink Partners | Upgrade | Outperform | $12 |
| 15 Jan 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 13 Nov 2024 | Leerink Partners | Downgrade | Market Perform | — |
| 13 Nov 2024 | Stifel | Maintains | Buy | — |
| 17 Oct 2024 | Leerink Partners | Maintains | Outperform | — |
| 13 May 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 25 Sept 2023 | Stephens & Co. | Reiterates | Overweight | — |
| 7 Feb 2023 | Stephens & Co. | Initiates | Overweight | — |
| 6 Jan 2023 | SVB Leerink | Maintains | Outperform | — |
| 15 Nov 2022 | SVB Leerink | Maintains | Outperform | — |
| 8 Mar 2022 | SVB Leerink | Maintains | Outperform | — |
| 14 May 2021 | SVB Leerink | Maintains | Outperform | — |
| 12 Jan 2021 | Cowen & Co. | Initiates | Outperform | — |
| 12 Jan 2021 | Stifel | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MASS.
This page is one stock. Monday covers all of them.
MASS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MASS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, 908 Devices, Inc. returned +52.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MASS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 5.5×
- Price / book
- 2.4×
- EV / EBITDA
- —
Cheaper than 20% of US stocks
Cheaper than 38% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 51.9%
- Operating margin
- −30.6%
- Net margin
- —
Higher than 64% of US stocks
Higher than 21% of US stocks
- Return on equity
- −16.8%
- Return on assets
- −6.5%
- Dividend yield
- —
Higher than 33% of US stocks
Higher than 30% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
908 Devices, Inc. has a market value of $360.5M and an enterprise value of $266.4M.
Revenue in the twelve months to 30 June 2026: $60.8M. The latest quarter grew 23.3% year on year.
Net income over the same four quarters: −$34.7M, a −57.0% net margin.
Diluted earnings per share, trailing twelve months: −$0.95.
Free cash flow in the twelve months to 30 June 2026: $615K.
908 Devices, Inc. employs 172 people — $354K of revenue per employee.
Data provided by Twelve Data
MASS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MASS’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own 908 Devices, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MASS
What is the MASS stock price forecast for 2026-2027?
The median 12-month analyst price target for 908 Devices, Inc. is $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MASS stock a buy right now?
Of the 6 analysts covering 908 Devices, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 908 Devices, Inc. 77 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MASS?
As at 21 Nov 2026, 908 Devices, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).
Will MASS stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts is $14, and Ticker Nerd's factor model ranks 908 Devices, Inc. 77 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MASS stock forecast for 2030?
No analyst covering 908 Devices, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MASS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $14 over the next 12 months.
How has MASS stock performed over the past year?
908 Devices, Inc. returned +52.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does 908 Devices, Inc. do?
908 Devices Inc. is a medical technology company that develops handheld and desktop chemical analysis instruments for point-of-need testing. Its product portfolio centers on portable mass spectrometry and spectroscopy systems used to detect, identify, and monitor unknown substances in demanding environments.
About 908 Devices, Inc.
908 Devices Inc. is a medical technology company that develops handheld and desktop chemical analysis instruments for point-of-need testing. Its product portfolio centers on portable mass spectrometry and spectroscopy systems used to detect, identify, and monitor unknown substances in demanding environments. The company’s devices support applications across health, safety, and defense, including field screening for hazardous chemicals, drugs, explosives, gases, and other materials that require rapid analysis outside traditional laboratories. 908 Devices also serves markets such as life sciences research, bioprocessing, biopharma, forensics, and industrial analysis with tools designed for faster, more accessible sample interrogation. Headquartered in Burlington, Massachusetts, 908 Devices focuses on making advanced analytical capabilities available in compact formats that can be used directly at the point of need.
CEO Dr. Kevin J. Knopp Ph.D. · 172 employees · United States · https://908devices.com